Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555408488> ?p ?o ?g. }
- W2555408488 endingPage "14172" @default.
- W2555408488 startingPage "14158" @default.
- W2555408488 abstract "// Cinta Hierro 1 , Analía Azaro 1 , Guillem Argilés 1 , Elena Elez 1 , Patricia Gómez 1 , Joan Carles 1 and Jordi Rodon 1 1 Department of Medical Oncology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain Correspondence to: Jordi Rodon, email: // Keywords : molecularly targeted agents, patient populations, window-of-opportunity, healthy volunteer, phase 0 Received : May 03, 2016 Accepted : October 26, 2016 Published : November 09, 2016 Abstract The introduction of new Molecularly Targeted Agents (MTA) has changed the landscape in Early Drug Development (EDD) over the last two decades, leading to an improvement in clinical trial design. Previous Phase 1 (Ph1) studies with cytotoxics focused on safety objectives, only recruiting heavily pre-treated cancer patients, have been left behind. In this review, we will illustrate the slow although unstoppable change that has increasingly been observed in those populations candidate to participate in EDD trials with the advent of MTA. As more evidence regarding oncogene addiction becomes available, molecular-biomarker driven selection has been implemented among Molecularly-Selected Population (MSP) studies. New Window-Of-Opportunity (WOO) and Phase 0 (Ph0) studies have been developed in order to assess whether a MTA produces the hypothetical proposed biological effect. The rising need of getting early pharmacokinetics and pharmacodynamics data has led to the conduction of Healthy Volunteer (HV) studies, in part favoured for the particular and different toxicity profile of these MTA. However, several challenges will need to be addressed in order to boost the implementation of these new clinical trial designs in the forthcoming years. Among the problems to overcome, we would highlight a better coordination effort between centers for ensuring adequate patient accrual among small patient populations and a deepening into the ethics implied in enrolling patients in studies with no therapeutic intent. However, these tribulations will be certainly compensated by the possibility of opening a new horizon of treatment for diseases with dismal prognosis." @default.
- W2555408488 created "2016-11-30" @default.
- W2555408488 creator A5016108968 @default.
- W2555408488 creator A5031165814 @default.
- W2555408488 creator A5053506951 @default.
- W2555408488 creator A5053880366 @default.
- W2555408488 creator A5059942977 @default.
- W2555408488 creator A5073714778 @default.
- W2555408488 creator A5075296860 @default.
- W2555408488 date "2016-11-09" @default.
- W2555408488 modified "2023-10-17" @default.
- W2555408488 title "Unveiling changes in the landscape of patient populations in cancer early drug development" @default.
- W2555408488 cites W1826437673 @default.
- W2555408488 cites W1889657886 @default.
- W2555408488 cites W1953808663 @default.
- W2555408488 cites W1971341357 @default.
- W2555408488 cites W1971837077 @default.
- W2555408488 cites W1974903221 @default.
- W2555408488 cites W1985995033 @default.
- W2555408488 cites W1988822126 @default.
- W2555408488 cites W1988910790 @default.
- W2555408488 cites W1995930366 @default.
- W2555408488 cites W1996713943 @default.
- W2555408488 cites W1999120252 @default.
- W2555408488 cites W1999659306 @default.
- W2555408488 cites W2000005501 @default.
- W2555408488 cites W2015431189 @default.
- W2555408488 cites W2021913096 @default.
- W2555408488 cites W2028714796 @default.
- W2555408488 cites W2029053821 @default.
- W2555408488 cites W2059744020 @default.
- W2555408488 cites W2059983371 @default.
- W2555408488 cites W2060224146 @default.
- W2555408488 cites W2064170540 @default.
- W2555408488 cites W2064969209 @default.
- W2555408488 cites W2066665319 @default.
- W2555408488 cites W2076809452 @default.
- W2555408488 cites W2088460013 @default.
- W2555408488 cites W2094652852 @default.
- W2555408488 cites W2099088585 @default.
- W2555408488 cites W2100374586 @default.
- W2555408488 cites W2104830962 @default.
- W2555408488 cites W2106494998 @default.
- W2555408488 cites W2106543129 @default.
- W2555408488 cites W2110017381 @default.
- W2555408488 cites W2110444464 @default.
- W2555408488 cites W2111662961 @default.
- W2555408488 cites W2114193543 @default.
- W2555408488 cites W2114281628 @default.
- W2555408488 cites W2117661783 @default.
- W2555408488 cites W2118682535 @default.
- W2555408488 cites W2118783030 @default.
- W2555408488 cites W2118812883 @default.
- W2555408488 cites W2125317841 @default.
- W2555408488 cites W2126314379 @default.
- W2555408488 cites W2127215555 @default.
- W2555408488 cites W2128542677 @default.
- W2555408488 cites W2129931005 @default.
- W2555408488 cites W2130594114 @default.
- W2555408488 cites W2133360223 @default.
- W2555408488 cites W2134787029 @default.
- W2555408488 cites W2135454149 @default.
- W2555408488 cites W2135836172 @default.
- W2555408488 cites W2139225734 @default.
- W2555408488 cites W2141275127 @default.
- W2555408488 cites W2141989396 @default.
- W2555408488 cites W2142752401 @default.
- W2555408488 cites W2146045158 @default.
- W2555408488 cites W2147960486 @default.
- W2555408488 cites W2150575159 @default.
- W2555408488 cites W2150700051 @default.
- W2555408488 cites W2151425644 @default.
- W2555408488 cites W2152060434 @default.
- W2555408488 cites W2161152839 @default.
- W2555408488 cites W2166084034 @default.
- W2555408488 cites W2166199281 @default.
- W2555408488 cites W2166242275 @default.
- W2555408488 cites W2166262263 @default.
- W2555408488 cites W2169363650 @default.
- W2555408488 cites W2169752008 @default.
- W2555408488 cites W2171608750 @default.
- W2555408488 cites W2171903499 @default.
- W2555408488 cites W2171972386 @default.
- W2555408488 cites W2186699971 @default.
- W2555408488 cites W2257446530 @default.
- W2555408488 cites W2296997770 @default.
- W2555408488 cites W2339905805 @default.
- W2555408488 cites W2341907329 @default.
- W2555408488 cites W2402374914 @default.
- W2555408488 cites W2464886513 @default.
- W2555408488 cites W3152573139 @default.
- W2555408488 cites W954457330 @default.
- W2555408488 doi "https://doi.org/10.18632/oncotarget.13258" @default.
- W2555408488 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5355170" @default.
- W2555408488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27835915" @default.
- W2555408488 hasPublicationYear "2016" @default.
- W2555408488 type Work @default.
- W2555408488 sameAs 2555408488 @default.